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1. Introduction 
There has been a debate since the 1980’s whether delusional depression or psychotic 
depression is a distinct psychiatric disorder. (Glassman & Roose, 1981) Currently, DSM-IV-
TR classifies psychotic symptoms in patients with major depressive disorder as a severity 
specifier. However, researchers in the area of major depressive disorder, with psychotic 
features (PMD) believe that PMD is a distinct disorder based on not only the 
phenomenological presentation, but family studies, course of illness, biological findings, and 
treatment as well. This lack of recognition of PMD as being a distinct disorder has 
contributed to the limited amount of research funding for this disorder in spite of a 
prevalence in the general population of 0.4-0.6%. (Johnson et al., 1991; Ohayon and 
Schatzberg, 2002) This chapter will provide an update on studies that support PMD as being 
a distinct psychiatric disorder. 
2. Phenomenology of PMD 
The DSM-IV-TR definition of PMD is major depressive disorder plus delusions or 
hallucinations. Early studies report that delusions occur in one half to two-thirds of adults 
and hallucinations occur alone in 3-25%. However, in our more recent studies, delusions 
co-occur with hallucinations in as many as 67% of patients with PMD. (Matthews 2002, 
2008) The most common delusions include: persecution, suspiciousness, paranoia, sin, 
guilt, ideas of reference, and somatic. (Frangos et al, 1983) Fifty percent or more 
experience more than one kind of delusion. (Dubovsky, 1992) Keller (2006) reported that 
patients with PMD score higher on unusual thought content, psychomotor retardation, 
and guilt then NPMD. Interestingly, a formal thought disorder occurs in only 20% of 
patients with PMD, thus, psychotically depressed patients who present with a formal 
thought disorder are more likely to have a diagnosis of either bipolar disorder or 
schizophrenia. The most common hallucinations are auditory and visual and they occur 
with equal frequency. (Schatzberg and Rothshild, 1992) Tactile and olfactory 
hallucinations may occur but usually with other types of hallucinations. In one study, 
olfactory hallucinations occurred in 40% of PMD patients. (Matthews et al., 2002) 
Dissociative symptoms in the absence of abuse may occur with greater frequency in PMD 
than NPMD. The psychotic symptoms of PMD may present as mood congruent or mood 
incongruent. In a study of 40 PMD inpatients , 26 (65%) had mood congruent (MC) and 14 
(35%) had mood incongruent (MI) psychotic symptoms; 71% of patients with MC 
experienced at least 1 MI symptom and 50% of patients with MI experienced at least 1 MC 
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psychotic symptom. (Burch et al., 1994) In a 10-year study by Maj et al. (2007), 10% of 452 
PMD patients had both MC and MI psychotic symptoms. Having MC or MI or both does 
not predict response to treatment or prognosis. (Rothschild, 2009)      
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Fig. 1. (Matthews et al., 2010) 
As with schizophrenia and bipolar disorder, patients with major depressive disorder exhibit 
cognitive deficits as a part of their clinical presentation. However, patients with PMD show 
greater  performance deficits  on specific neuropsychological tasks than patients with major 
depressive disorder, without psychotic features (NPMD). (Gomez et al., 2006) In addition, 
patients with PMD demonstrate more difficulty processing, manipulating and encoding 
new information than patients with NPMD (Gomez et al., 2006) In a meta-analysis of five 
studies, Fleming et al. (2004) showed that patients with PMD scored significantly lower on 
neuropsychological measures of executive function, verbal memory, and psychomotor 
speed than patients with NPMD.  
We also found that found that patients with PMD scored significantly lower on executive 
function, verbal memory, and psychomotor speed than patients with NPMD. (Figure 1) 
(Matthews, et al., 2010)The mean scores on these three measures for PMD were greater than 
one standard deviation below the mean for the general population. The total score on the 
BPRS predicted the lower scores on executive function, verbal memory, and psychomotor 
speed, whereas, the HAM-D-17 did not. We also found that these cognitive deficits 
significantly improved with remission of PMD; thus, the cognitive deficits were state 
dependent (Table 1). 
In order to control for the possible impact of medications on cognitive function, Hill et al., 
(2004) studied first episode PMD, Schizoaffective, Schizophrenia versus NPMD and healthy 
controls. There were significant differences between PMD and NPMD on several 
neuropsychological tasks; however, PMD was more similar to, but less severe, than 
performances by first break schizophrenics. (Figure 2) Hill hypothesized that the cognitive 
deficits found in PMD and schizophrenia may involve similar brains systems. 
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• Executive function 
- Pre -Treatment  87.76 (±18.89) 
- Post -Treatment  94.52 (±15.58) *  
• Memory 
- Pre-Treatment  90.85 (±10.87) 
- Post- Treatment  97.57 (±14.36)  
• Psychomotor 
- Pre-Treatment  88.82 (±30.51)* 
- Post-Treatment 103.77 (±25.39) * 
* p < .01 
Table 1. (Matthews, et al., 2010) 
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Fig. 2. (Hill et al., 2004; adapted) 
3. Differential diagnoses 
The diagnosis of PMD is often missed. Rothschild et al., (2008) found that in the NIMH 
Study of Pharmacotherapy of Psychotic Depression (STOP-PD), which was located at 4 
academic medical centers, only 65% (85/130) of clinicians made an accurate diagnosis. 
Missed diagnoses on inpatient units were significantly less than in the emergency room; 
18% (13/74) versus 39% (22/56) (χ2=7.64, p<.01) respectively. Distinctions between PMD 
and schizoaffective disorder or bipolar disorder are most problematic. In schizoaffective 
disorder, psychotic symptoms are not confined to mood disturbance, whereas, in PMD, 
psychotic symptoms co-occur with symptoms of depression.  However, Maj et al., (2007) 
found that 10% of PMD with mood incongruent psychosis met criteria for schizoaffective 
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disorder, depressed type. Studies have shown that a subset of patients with PMD eventually 
experience a manic or hypomanic episode. This is particularly true for early onset PMD. 
Between 40-75% of adolescents with PMD convert to bipolar disorder (Askiskal et al., 1983; 
Strober and Carlson, 1982). Maj et al., (2007) found a switch rate of 10.1% for PMD versus a 
switch rate of 5% for NPMD in an adult population (n=452) over a 10-year period. 
4. Family studies/genetics 
There is limited data to support PMD as being a genetic disorder. In the case of NPMD, twin 
studies have demonstrated that there is a genetic factor that is passed on from one 
generation to the next. In a review of twin studies in NPMD, Sullivan and Kendler (2001) 
estimated heritability to be 37%, with a significant component of individual environmental 
risk. Brown et al., (1994) found that only 20% of patients with PMD could identify a 
significant stressor in the 6 month period prior to a new episode onset compared to 72% in 
patients with NPMD. These results might reflect differences in the procurement of 
homogeneous populations or the genetic loading or both. Rothschild (2009) summarized the 
family studies of first degree relatives comparing PMD and NPMD and found that the first 
degree relatives of PMD had higher rates of PMD, higher rates of bipolar disorder by a 
factor of 6 (Weissman et al., 1984), higher rates of cyclothymia in children by a factor of 3 
(Weissman et al., 1988), and higher rates of NPMD if PMD probands had a post-
dexamethsone serum cortisol of >15 ug/dl (Bond et al., 1986). A number of candidate genes 
have been have been proposed including genes for: dopamine-β-hydroxylase (DBH); 
dopamine D4 receptor gene; glycogen synthase kinase-3 gene; and serotonin transporter 
gene ( 5-HT1A; 5-HT2C; 5-HT 2A receptor gene). The gene for the DBH activity has been 
most promising based on the findings that five of six studies have shown decreased DBH 
activity in PMD. (Rothschild, 2009) Schatzberg et al., (1985) have hypothesized that a 
decrease in DBH enzyme activity may be important as to why depressed patients may 
become psychotic; reduced DBH activity results in a decrease in conversion of dopamine to 
norepinephrine thus increasing the availability of dopamine. The gene encoding DBH is 
located on chromosome 9q34; the adenosine allele predicts psychosis. (Craig et al., 1998; 
Wood et al., 2002) 
5. Comorbidity 
There is very little literature on the co-morbid psychiatric disorders in PMD. In a clinical 
trial of the combination of olanzapine plus fluoxetine, Matthews et al., (Figure3)  found that 
anxiety disorders were among the most common; especially panic disorder. 
6. Biology of PMD 
Although there have been a few EEG and imaging studies using CT and MRI scans in 
depression, the most consistent findings have been with the dysregulation of the 
hypothalamic-pituitary-adrenal axis (HPA-axis). Table 2 summarizes the findings. 
Researchers have know since the 1970’s that cortisol is elevated in patients with NPMD 
(Carroll et al. 1981; Brown et al., 1985); however, the dysregulation of the HPA-axis is even 
more pronounced in PMD. Twenty-four hour urinary free cortisol is significantly higher in 
PMD than in NPMD and patients with PMD also have higher rates of dexamethasone  
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Fig. 3. (Matthews et al., 2002) 
 
• ↑ cortisol in urine, blood, and CSF 
• ↑ cortisol response to ACTH 
• ↑ size of both pituitary and adrenal glands 
• ↑ secretion of CRH 
• ↑ CRH in CSF 
• ↑ CRH messenger RNA in PVN  
•  ↑ ACTH response to CRH challenge  
Table 2. Evidence for HPA-axis Hyperactivity 
stimulation test (DST) non-suppression than patients with NPMD. (Nelson and Davis, 1997; 
Schatzberg et al., 1992) The presence of psychotic symptoms accounts for most of the 
variance and severity of depression does not account for the differences. (Schatzberg et al., 
1992) In a meta-analysis of 14 studies (12/14 inpatient), the DST non-suppression rates were 
64% for PMD (n=276) and  41% for NPMD (n=708) (p<0.001) with a sensitivity of 64% and 
specificity of 59% using a post-dexamethasone cortisol serum level cut off of ≥5 ug/dL. 
(Nelson & Davis, 1997) These differences between PMD and NPMD DST non-suppression 
appear to be due to the presence of psychosis since Nelson and Davis, in another meta-
analysis of 19 studies of NPMD, showed that there were no significant differences in DST 
non-suppression rates of inpatients with or without melancholic features; the rates were 
38% versus 33% respectively (p=0.74) The DST non-suppression rate for non-melancholic 
outpatients (n=138) was 12%. Using a cut off for DST non-suppression of ≥15 ug/dL, 
Schatzberg et al., (1983) improved on the specificity (93%) but, not on the sensitivity (50%) of 
DST. Rothschild et al., (1982) demonstrated that the DST distinguished PMD from  
schizophrenia; the DST non-suppression rate for PMD was 57% and 0% for psychotic 
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schizophrenics. The dysregulation of the HPA-axis is a state rather than a trait phenomenon. 
There is normalization of the HPA-axis with treatment (Carroll et al., 1981). Using the 
combined DST and corticotropic releasing hormone (CRH) infusion test, Kunugi et al. (2006) 
reported significant decreases in ACTH (p=.007) and cortisol (p=.002) levels with response 
to treatment in patients with PMD. 
The mechanism for the hyperactivity of the HPA-axis is based on studies that suggest 
glucocorticoid-mediated feedback impairment at the level of the pituitary and 
hypothalamus. (de Kloet et al.,1998; Young et al., 1991) Specifically, glucocorticoid receptors 
are located in the cytoplasm of cells and consist of two types, GR I and GR II. The GR I 
receptors are the high affinity receptors for endogenous glucocorticoids and are responsible 
for the diurinal regulation of cortisol; whereas, the GR II receptors are the low affinity 
glucocorticoid receptors and are important when cortisol levels are high, such as in stress or 
depression. It is hypothesized that, in depression, there is an impairment in the translocation 
of the glucocorticoid receptor from the cytoplasm into the nucleus; once activated by 
cortisol, the glucocorticoid receptor translocates  in to the nucleus to complete the feedback 
by binding to DNA. (Figure 4; adapted) (Parionte and Miller, 2001; adapted) Interestingly,  
 
 
Fig. 4. (Parionte & Miller, 2001; adapted) 
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preclinical studies have shown that serotonin re-uptake blockers (SSRIs) and tricyclic 
antidepressants (TCAs) facilitate the translocation of the activated glucocorticoid receptors 
from the cytoplasm to the nucleus. Parionte and Miller (2001) suggest that this mechanism 
may provide one possible explanation for how treatment with antidepressants results in 
normalization of the HPA-axis hyperactivity in patients with depression.    
While there was research focusing on HPA-axis dysregulation, there was another line of 
research evaluating dopamine (DA) activity in PMD versus NPMD. Previous studies have 
shown that CSF levels of a metabolite of DA, homvanillic acid (HVA), are low in patients 
with NPMD. (Sher et al., 2006; Reddy et al., 1992) However, Rothschild et al., (1987) showed 
that DA plasma levels are elevated in PMD, but not in NPMD. Others have shown that HVA 
is elevated in blood and CSF in PMD, but not in NPMD. (Sweeney et al., 1978; Aberg-
Wistedt et al., 1985) The relationship between the findings of HPA-axis dysregulation and 
elevated DA in PMD was realized by Langlais et al., (1984; 1985) and others (Wolkowiz et 
al., 1986; Rothschild et al., 1984, 1987;  Banki et al., 1983) who showed that glucocorticoids 
can increase DA in rat brain and human plasma and increase HVA in rat brain and human 
CSF. Based on these findings, Schatzberg and Rothschild hypothesized that psychotic 
symptoms in depression were secondary to the effects of hypercortisolemia on DA systems. 
(Schatzberg & Rothschild, 1992; Schatzberg et al.,1985)  Maguire et al., (1987) showed a 
positive correlation between plasma free HVA and post dexamethasone log plasma cortisol 
levels (r=0.59; p=0.02).  
7. Treatment straegies for PMD 
The observations that DA activity is elevated in PMD have provided the rationale for the 
findings that antipsychotic medications significantly improve response rates when combined 
with antidepressant medications. Spiker et al., (1985) carried out one of the first randomized, 
double-blind prospective studies. Patients were randomized to amitriptyline monotherapy, 
perphenazine monotherapy, or combined amitriptyline plus perphenazine over a 5 week 
period; the response rates were 41% (7/17), 19% (3/16), and 78% (14/18) respectively. These 
results established the standard of practice of using combined antidepressant and 
antipsychotic medications for the treatment of PMD from that point forward. With the 
introduction of SSRIs, SNRIs, atypical antidepressants and atypical antipsychotic medications, 
there have been new treatment strategies using SSRI or SNRI monotherapy, atypical 
antipsychotic monotherapy, or atypical antipsychotic medications combined with an SSRI, or 
SNRI. In a series of 6-week treatment studies of PMD using SSRI or SNRI monotherapy, Gatti 
et al., (1996) and Zanardi et al., (1996;2000) showed high remission rates with fluvoxamine 
(84%), sertraline (72%), and venlafaxine (50%). In addition, Zanardi et al., (1997), in a 30 month, 
maintenance, open study of fluvoxamine remitters, found a relapse rate of only 20%. However, 
these studies lacked a control group and a validated instrument for the identification of 
psychosis.( Rothschild & Phillips, 1999) In addition, there has been no replication of these 
results. In an 8-week open study comparing the efficacy of sertraline monotherapy in PMD 
(n=25) versus NPMD (n=25)), Simpson et al., (2003) found remission rates of 16% and 64% in 
patients with PMD and NPMD respectively (p=.001).  
The atypical antipsychotics block both 5-HT2 and DA receptors, which, theoretically, make 
them potential candidates for treating both depression and psychosis. There was a series of 
case reports and small open studies in the 1990’s suggesting that atypical antipsychotic 
monotherapy was effective in treatment resistant PMD. (Ranyan and Meltzer, 1996; Dassa et 
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al., 1993; Lane and Chang 1998; Hillert et al., 199) To test the efficacy of atypical 
antipsychotic monotherapy, Muller-Siecheneder et al., (1998) compared the efficacy of 
risperidone monotheray (n=16) versus the combination of haloperidol and amitriptyline 
(n=18) in the treatment of PMD. Both arms of the study showed improvement in depression 
and psychosis, but combined treatment was significantly better than monotherapy on scores 
for depression, BRMES, (p=.002) and psychosis, BPRS, (p=.016) More recent studies also 
support the value of combined atypical antipsychotic and antidepressant medications over 
atypical antipsychotic monotherapy. Rothschild et al., (2004) reported on two identical 
parallel trials where PMD patients were randomized to combined olanzapine/fluoxetine 
(OFC), olanzapine monotherapy (OLAN), or placebo (PLB); the HAM-D-24 response rates 
were 63.6%, 34.9%, and 28% respectively in Trial 1. Olanzapine/fluoxetine response rates 
were significantly higher than OLAN monotherapy (p=.027) and PLB (=.004). There were no 
significant differences among the three arms in Trial 2. (Figure 5) 
 
34.9 36.2
28
31.8
63.6*
47.8
0
10
20
30
40
50
60
70
Trial 1 (n=124) Trial 2 (n=125)
Olanzapine
Placebo
OFC
 
Fig. 5. (Rothschild et al., 2004; adapted) 8-Week Randomized Trial Olanzapine vs. OFC vs. 
Pl (HAM-D-24 Response Rates - Trial: 1 OFC vs. Olan *p=.027; OFC vs. Pl p=.004)   
The only other randomized clinical trial comparing combined atypical 
antipsychotic/antidepressant with atypical antipsychotic monotherapy was the STOP-PD 
study, A National Institutes of Mental Health funded, multi-center study, reported by 
Meyers et al., (2009). (Figure 6) 
In the STOP-PD study, patients were randomized to olanzapine plus sertraline 
(OLAN/SERT) (n=129) or olanzapine plus placebo (OLAN/PLB) (n=130) and treatment was 
continued for 12 weeks. The OLAN/SERT group remission rate separated from the 
remission rate for the OLAN/PLB group at week-8; the remission rate for OLAN/SERT 
continued to be significantly better than the remission rate for the OLAN/PLB group 
through week-12 (Hochberg α level of .05 from χ2 analysis). Remission rates at last 
assessments were 41.9% and 23.9% for the OLAN/SERT and OLAN/PLB groups 
respectively. There is only one randomized controlled study comparing combined atypical 
antipsychotic and antidepressant medications with antidepressant monotherapy. Wijkstra et 
al., (2010a), in a 7-week trial, randomized patients to combined quetiapine plus venlafaxine   
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Fig. 6. (Meyer et al., 2009; adapted) STOP-PD: Remission for Olan + Sertraline vs. Olan + 
Placebo  (* Hochberg α level of .05 from χ2 analysis) 
(QUET/VEN) (n=42), venlafaxine monotherapy (VEN) (n=39), or impramine monotherapy 
(IMI) (n=41). There were no significant differences among the three groups with regards to 
remission rates. However, there was a significant difference with regards to HAM-D-17 
response rates (response rate=50% reduction in HAM-D-17 from baseline and HAM-D-17 
score at endpoint of ≤14) between QUET/VEN versus VEN (RD=32.5{95%CI:11.8; 53.2) at 
week-7. Based on these four randomized controlled studies, combined treatment with an 
atypical antipsychotic  medication with an antidepressant is recommended. There have been 
no randomized controlled studies with the partial dopamine agonist, aripiprazole. In an 
open study, Matthews et al., (2009) published the first study combining aripiprazole with 
the SSRI, escitalopram. (Figure 7) Patients on this combination treatment showed remission 
rates of 42% by week-4 and 50% by week-7. Matthews et al., (2009) suggested that this rapid 
response may be due to the possibility that the SSRI, escitalopram, augmented the 
antipsychotic effect of aripiprazole through the established relationship of raphe nucleus 
serotonin inhibitory activity on ventral tegmental area dopamine cells and the possible 
augmentation of escitalopram by aripiprazole through 5HT2A blocking.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. ( Matthews et al., 2009; adapted) PMD Remission Times: Aripiprazole/Escitalopram  
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Studies by Rothschild et al., (1999) and Kaiya et al., (1990 ) suggest that atypical 
antipsychotics are superior to typical antipsychotic medications for the treatment of PMD 
based on efficacy and time to response. Based on current findings, the ideal treatment for 
PMD might be the combination of an atypical antipsychotic with either an SSRI or SNRI; 
however, there needs to be a head-to-head trial comparing an SSRI or SNRI with a 
norepinephrine uptake blocker in combination with an atypical antipsychotic medication in 
order to validate this hypothesis. (Matthews, et al., 2009) 
Recent research has used a novel approach for the treatment of PMD by targeting the HPA-
axis hyperactivity associated with PMD. (Thakore & Dinan, 1995) There have been two 
strategies, inhibition of cortisol synthesis and blockade of the GR II receptors with 
antagonists. In a 4-week randomized, double blind, placebo controlled study of 20 
medication –free NPMD patients, eight of whom had elevated cortisol levels, Wolkowitz et 
al., (1999) randomized patients to ketoconazole (400-800 mg/d) or placebo for 4 weeks. 
Ketoconazole was associated with improvements in depression ratings only in those 
patients with elevated cortisols. Forty-eight percent of ketoconazole treated 
hypercortisolemic patients showed a significant drop in HAM-D-21 compared to 6.6% of the 
placebo group (p<.03). In preclinical studies, mifepristone has been shown to be an 
antagonist at the GR II receptor. (de Kloet et al., 1998)  This finding has lead to a series of 
studies assessing the efficacy and safety of mifepristone (RU486) in the treatment of PMD. 
Early studies by Belanoff et al., (2001, 2002) and Simpson et al., (2003) (Figure 8) 
demonstrated improvement in both depression and psychosis in a dose dependent manner. 
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Fig. 8. (Simpson et al., 2005 adapted)   Mifepristone: N=20; 6-week course; open-label; LOCF  
However, more recent studies point to psychosis as the primary target of response. (DeBattista 
et al., 2006)  Blasey et al., (2009), in a multi-site study (n=29), 56 day, placebo controlled study, 
demonstrated a rapid reduction in the Brief Psychiatric Rating Scale-Positive Symptoms 
Subscale (BPRS-PSS) in only 7 days with mifepristone compared to placebo; response rates 
were defined as a 50% reduction in BPRS-PSS from baseline at both days 7 and 56. BPRS-PSS 
response rate was determined by mifepristone plasma level. (Figure 9)  
Patients with mifepristone plasma levels ≥1800 ng/ml were more likely to respond than 
patients on placebo; however, there were differences in responses between the original 20 
research sites versus the 9 added research sites (Intent-to-treat: OR=2.4, p=.03; Initial sites: 
OR=4.1, p=.002).  
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Fig. 9. (Blasey et al., 2009; adapted) Mifepristone: BPRS-PSS Response Rate at Days 7 and 56 
(50% ↓ from Baseline; p=.018) (n=207)  
Electroconvulsive therapy has been shown to be very effective in treating both 
neurovegetative symptoms of depression and psychosis. In an early review by Solan et al., 
(1988 ) they concluded that ECT response rates in PMD were not significantly different than 
the response rates in NPMD. However, two more recent studies have shown that the 
presence of psychosis is a predictor of ECT response in major depressive disorder. Petrides 
et al., (2001) found that completer remission rates for PMD (n=77) versus NPMD (n=176) 
were 95% and 83% respectively. Figure 10) 
 
76%
78%
80%
82%
84%
86%
88%
90%
92%
94%
96%
Complete
PMD
NPMD
 
Fig. 10. (Petrides et al., 2001,adapted) ECT Remission Rates in Psychotic vs. Nonpsychotic 
MDD 
In an European study, Birkenhager et al., (2003) found response rates of 92% and 55% in 
delusional depression versus non delusional depression respectively; remission rates were 
57% and 24% respectively. (Figure 11) 
• PMD (n=77) vs. NPMD 
(n=176) 
• Remission rates ≤ 10 on 
HAM-D 24 
• Bilateral ECT 
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Fig. 11. (Birkenhager et al., 2003; adapted) ECT Response in Delusional vs. Non-delusional 
Depressed Inpatients 
There is no evidence that psychotherapy alone is effective in the treatment of PMD as is the 
case for mild to moderate NPMD outpatients. (Rush et al., 1977) Gaudiano and Herbert 
(2006) combined Acceptance and Commitment Therapy (ACTto enhanced treatment as 
usual (ETAU) (n=19) versus ETAU (n=21) in an inpatient populations of PMD. Acceptance 
and Commitment Therapy focuses on acceptance of one’s distress rather than ruminating 
about contributing factors from the past and/or worries about future negative predictions, 
both of which are out of one’s absolute control. Acceptance allows one to observe one’s 
distress as an opportunity to learn and thus improve problem solving. Acceptance also 
enables one to proceed with achieving value-based goals; thus, with acceptance, value-based 
goals can be achieved in spite of one’s distress. Gaudiano and Herbert taught patients to 
accept their psychotic symptoms without judgment and to proceed with achieving their 
value-based goals. For their primary outcome measure, they found that 44% of ACT+ETAU 
versus 0% of ETAU had a ≥ 2 standard deviation improvement at discharge from baseline 
on total BPRS (χ2=5.14, p<.05). In addition, there were no significant differences in change 
scores from baseline to discharge  between the two groups on the BPRS-PSS subscale, but 
the percent change scores on the  BPRS mood subscale from baseline to discharge for 
ACT+ETAU versus ETAU were 70% and 30% respectively (χ2=3.60, p=.058). 
8. Longitudinal course of PMD 
Patients with PMD have a more severe course to their illness compared to patients with 
NPMD. At one year follow-up, patients with PMD were more likely to be in an episode, had 
significantly higher numbers of episodes, and psychiatric hospitalizations. (Robinson and 
Spiker, 1985) Data from the Epidemiology Catchment Area (ECA) study found that patients 
with PMD, compared with NPMD, have significantly greater impairment in functioning as 
measured by percent on public assistance (17.5% of PMD; 7.2%of NPMD) and on disability 
(15.9% of PMD; 6.7% of NPMD). (Johnson et al., 1991) As with schizophrenia and bipolar 
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disorder, PMD is associated with higher rates of morbidity and mortality from medical 
conditions. Vythilingam et al., (2003) found that the mortality rate was two-fold higher for 
PMD versus NPMD and that 88% of the deaths were due to medical disorders. 
In a 10-year prospective study, Coryell, et al., (1996) found that patients with PMD spent 
more weeks in full major depressive disorder than patients with NPMD. (Figure 12) 
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Fig. 12. (Coryell et al., 1996; adapted) Number of Weeks in Full Major Depression  (10 
YEARS) (*p < .05; **p < .01) 
They also found that the recovery period was significantly prolonged with PMD versus 
NPMD. The percents of patients who had not recovered from their index episodes of PMD 
versus NPMD were 36.4% versus 28.2% at year-1 (p<.05), 19.7% versus 7.8% at year- 5 
(p<.001), and 14.3% versus 4.6% at year-10 (p<.001) respectively. However, when compared 
to schizophrenia, Tsaung and Coryell, (1992) showed that  recovery rates from index 
psychotic episodes were significantly better for PMD versus schizophrenia: 54% versus 4% 
at year-1, 75% versus 18% at year- 5; and 75% versus 21% at year-8 respectively (Wilcoxon 
χ2=15.4, df=1, p<0.0001). Wijkstra et al., (2010b) showed that remission rates continue to 
improve by 27.5% over a 4-month continuation of the same medications that resulted in 
meeting criteria for response at week-7. Thus, for patients who have responded partially, 
but have not achieved remission, continuation of treatment for another few months may 
provide added benefit.  
As noted above, PMD is a highly relapsing disorder. Aaronson et al., (1988) reported on a 3-
year retrospective study of 52 PMD inpatients who had achieved remission by discharge. 
Forty-five of the 52 patients (86%) relapsed over the 3-year period following discharge. 
There were 98 episodes of relapse among the 45 patients who relapsed. Eight-two (82.5%) of 
the 98 episodes occurred within the first year after discharge from inpatient treatment. 
Seventy-one (86%) of the first year relapses occurred with patients on no antipsychotic 
medications or tapering doses of antipsychotic medications. Twenty-nine (41%) of the 71 
relapses associated with antipsychotic medications changes occurred despite stable doses of 
antidepressants. The relapse rate for patients on stable doses of antidepressant and 
antipsychotic medications during year-1 was 13.4%. In addition, 42% of the first year 
relapses occurred in the first 3-month period of discontinuation or decrease in dose of 
antipsychotic medications. Aronson et al., (1988) concluded that combined treatment with 
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antipsychotic and antidepressant medications beyond the first year of recovery is 
recommended. Coryell, et al., (1996) reported on the percent of PMD patients on 
antidepressant and antipsychotic medications at the time of first relapse after achieving 
remission. They found 48 % were on antidepressant but only 20% were on antipsychotic 
medications. 
There have been few accessible guidelines available for clinicians to use  in deciding 
maintenance treatment of PMD. In a survey of 304 practicing clinicians, who were attending 
a psychopharmacology course sponsored by the Department of Psychiatry at Massachusetts 
General Hospital in 2001, Matthews, (2001) queried clinicians as to whether they continued 
their PMD patients on antidepressant and antipsychotic medications beyond 12 months 
after they achieved remission. Fifty-six percent of the clinicians indicated that they 
continued antidepressant medications beyond 12 months, whereas, only 16% reported that 
they continued antipsychotic medications beyond 12 months. Rothschild and Duval, (2003) 
provided potential guidelines for clinical decision making regarding maintenance treatment 
for PMD. They reported on 40 patients diagnosed with PMD who had achieved remission 
after 5 weeks of acute treatment with the combination of perphenazine plus fluoxetine. 
These patients were continued on the combination treatment for an additional 4 months; at 
the end of the 4-month continuation phase, they were tapered off perphenazine and 
continued on fluoxetine monotherapy for an additional 8 months of maintenance treatment. 
There were no relapses during the 4-month continuation phase; however, 8 (27%) of the 30 
patients who continued into the maintenance phase relapsed. Rothschild and Duval 
reported that the predictors of relapse included a longer index episode, a history of more 
frequent episodes, an earlier age of onset of PMD, and less than 30 years of age at index 
episode. In the recent STOP-PD study, Andreescu et al., (2007) reported on the adequacy of 
pharmacological treatment on the first 100 patients at study entry. The rates of adequate or 
high doses of antidepressants, antipsychotics, and combined antidepressant/antipsychotic 
medications were 48%, 6%, and 5% respectively. 
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Fig. 13. (Andreescu et al., 2007; adapted) STOP-PD: Adequate Pharmacological Treatment 
on Study Entry (n=100)       
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(Figure 13)  Interestingly, these finding are comparable with results reported by Mulsant et 
al. (1997), who found  that only 4% (2/53) of PMD patients referred for ECT received an 
adequate medication trial, whereas 52% (70/134) of NPMD patients received an adequate 
medication trial. In addition, 47% (25/53) of PMD received either no antipsychotic 
medication or the duration treatment with an antipsychotic medication was for less than 
three weeks. Only 15% received antipsychotic doses greater than 200 mg daily of 
chlorpromazine equivalents. Thus, it appears that prescribing practices for PMD had not 
changed significantly for the 10- year period from 1997 to 2007. (Figure 14) Unfortunately, 
there have been very few acute and long-term clinical trials for the treatment of PMD 
compared with NPMD, bipolar disorder, or schizophrenia; thus, there is minimal data 
available to serve as a guideline for practicing clinicians.  
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Fig. 14. (Andreescu et al., 2007; adapted) STOP-PD: % Receiving Adequate Antipsychotics at 
Study Entry in 2005 vs. 1997   
9. Conclusions 
Combined antidepressant and antipsychotic treatment continues to be the standard for 
acute and maintenance treatment of PMD. Selective Serotonin Reuptake Inhibitor 
monotherapy may be effective in treating PMD during the acute, continuation, and 
maintenance phases; however, there advantage may be in helping to augment atypical 
antipsychotic medications in treating psychotic symptoms, but further studies are required. 
Atypical antipsychotics in combination with SSRIs may increase the response rate and 
decrease the time to response. SSRIs may augment atypical antipsychotics by inhibiting DA 
cells and atypical antipsychotics may augment SSRIs by blocking 5HT 2A receptors; 
however, studies are needed to support these hypotheses. Preliminary data suggests 
mifepristone, a glucocorticoid receptor antagonist, treats psychotic symptoms in PMD 
rapidly and the response has durability beyond discontinuation of the drug after only 7 
days of treatment. Psychotic features in major depressive disorder predict response to ECT. 
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Psychotic major depression is a highly relapsing illness with a long recovery period, 
therefore, long-term prophylactic treatment with combined antidepressant and an 
antipsychotic medications is recommended. 
10. References 
Aberg-Wistedt, A., Wistedt, B., Bertilsson, L., Higher (1985). Higher CSF Levels of HVA and 
5-HIAA in Delusional Compared to Nondelusional Depression (letter). Arch Gen 
Psychiatry, Vol. 42 (1985), pp. 925-926, ISSN 0003-990X. 
Akiskal, H.S., Walker, P., Puzantian, V.R., et al (1983). Bipolar Outcome in the Course of 
Depressive Illness: Phenomenological, Familial, and Pharmacologic Predictors. 
Journal of Affective Disorders, Vol. 5 (1983), pp. 115-128, ISSN 0165-0327. 
American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders 
(4th edition), American Psychiatric Association, ISBN 0890420645, Washington, DC. 
Andreescu, C., Mulsant, B.H., Peasley-Micklus, C., et al (2007). The Study of 
Pharmacotherapy of Psychotic Depression (STOP-PD) Collaborative Study Group: 
Persisting Low Use of Antipsychotics in the Treatment of Major Depressive 
Disorder with Psychotic Features. Journal of Clinical Psychiatry, Vol. 68 (2007), pp. 
194-200. 
Andreescu, C., Mulsant, B.H., Peasley-Miklus, C., Rothschild, A.J., Flint, A.J., Heo, M., 
Caswell, M., Whyte, E.M. & Meyers, B.S. (2007). Persisting Low Use of 
Antipsychotics in the Treatment of Major Depressive Disorder with Psychotic 
Features. Journal of Clinical Psychiatry, Vol.68, No.2, (February 2007), pp. 194-200, 
ISSN 0160-6689 
Aronson, T.A., Shukla, S., Gujavarty, K., Hoff, A., DiBuono, M. & Khan, E. (1988). Relapse in 
Delusional Depression: a Retrospective Study of the Course of Treatment. 
Comprehensive Psychiatry, Vol.29, No.1, (January-February 1988), pp. 12-21, ISSN 
0010-440X 
Banki, C.M., Arato, M., Papp, Z. (1983). Cerebrospinal Fluid Biochemical Examinations: Do 
They Reflect Clinical or Biological Differences? Biological Psychiatry, Vol. 18 (1983), 
pp. 1033-1044, ISSN 0006-3223. 
Belanoff, J.K., Flores, B.H., Kalezhan, M., Sund, B. & Schatzberg, A.F. (2001). Rapid Reversal 
of Psychotic Depression Using Mifepristone. Journal of Clinical Psychopharmacology, 
Vol.21, No.5, (October 2001), pp. 516-521, ISSN 0271-0749 
Belanoff, J.K., Rothschild, A.J., Cassidy, F., DeBattista, C., Baulieu, E.E., Schold, C. & 
Schatzbert, A.F. (2002). An Open Label Trial of C-1074 (Mifepristone) for Psychotic 
Major Depression. Biological Psychiatry, Vol.52, No.5, (September 2002), pp. 386-
392, ISSN 0006-3223 
Birkenhager, A.K., Pluijms, E.M. & Lucius, S.A.P. (2003). ECT Response in Delusional versus 
Non-Delusional Depressed Inpatients. Journal of Affective Disorders, Vol.74, No.2, 
(April 2003), pp. 191-195, ISSN 0165-0327 
Blasey, C.M., DeBattista, C., Roe, R., Block, T. & Belanoff, J.K. (2009). A Multisite Trial of 
Mifepristone for the Treatment of Psychotic Depression: A Site-by-Treatment 
Interaction. Contemporary Clinical Trials, Vol.30, No.4, (July 2009), pp. 284-288, ISSN 
1551-7144 
www.intechopen.com
 
An Update on Psychotic Depression 
 
255 
Bond, T.C., Rothschild, A.J., Lerbinger, J., et al (1986). Delusional Depression, Family, 
History, and DST Response: A Pilot Study. Biological Psychiatry, Vol. 21 (1986), pp. 
1239-1246, ISSN 0006-3223. 
Brown, W.A., Keitner, G., Qualls, C.B., Haier, R. (1985). The Dexamethasone Suppression 
Test and Pituitary-adrenocortical Function. Arch Gen Psychiatry, Vol. 42, No. 2 
(February 1985), pp. 121-3, ISSN 0003-990X. 
Brown, G.W., Harris, T.O., Hepworth, C (1994). Life Events and Endogenous Depression: A 
Puzzle Re-examined. Arch Gen Psychiatry, Vol. 51, No. 7 (Jul 1994), pp. 525-34, 0003-
990X. 
Burch, E., Anton, R., Carson, W. (1994). Mood Congruent and Incongruent Psychotic 
Depressions: Are They the Same? Journal of Affective Disorders, Vol. 31 (1994), pp. 
275-280, ISSN 0165-0327. 
Carroll, B.J., Feinburg, M., Greden, J.F., Tarika, J., Albala, A.A., Haskett, R.F., James, N.M., 
Kronfol, Z., Lohr, N., Steiner, M., de Vigne, J.P., Young, E. (1981). A Specific 
Laboratory Test for the Diagnosis of Melancholia: Standardization, Validation, and 
Clinical Utility. Arch Gen Psychiatry, Vol. 38, No. 1 (January 1981), pp. 15-22. 
Coryell, W., Leon, A., Winokur, G., Endicott, J., Keller, M., Akiskal, H. & Slomon, D. (1996). 
Importance of Psychotic Features to Long-Term Course in Major Depressive 
Disorder. American Journal of Psychiatry, Vol.153, No.4, (April 1996), pp. 483-489, 
ISSN 0002-953X 
Craig, S.P., Buckle, V.J., Lamouroux, A., et al (1998). Dopamine Beta-Hydroxylase: Two 
Polymorphisms in Linkage Disequilibrium at the Structural Gene DBH Associate 
with Biochemical Phenotypic Variation. Human Genetics, Vol. 102 (1998), pp. 533-
540, ISSN 0301-0171. 
Dassa, D., Kaladjian, A., Azorin, J.M. & Giudicelli, S. (1993). Clozapine in the Treatment of 
Psychotic Refractory Depression. British Journal of Psychiatry, Vol.163, (December 
1993), pp. 822-824, ISSN 0007-1250 
DeBattista, D., Belanoff, J., Glass, S., Khan, A., Horne, R.L., Blasey, C., Carpenter, L.L. & 
Alva, G. (2006). Mifepristone versus Placebo in the Treatment of Psychosis in 
Patients with Psychotic Major Depression. Biological Psychiatry, Vol.60, No.12, 
(December 2006), pp. 1343-1349, ISSN 0006-3223 
De Kloet, E.R., Vreugdenhil, E., Oitzl, M.S., Joels, M. (1998). Brain Corticosteroid Receptor 
Balance in Health and Disease. Endocrine Reviews, Vol. 19, No. 3 (1998), pp. 269-
301, ISSN 0163-769X. 
Dubovsky, S.L. & Thomas, M. (1992). Psychotic Depression: Advances in Conceptualization 
and Treatment. Hospital and Community Psychiatry, Vol.43, No.12, (December 1992), 
pp. 1189-1198, ISSN 0022-1597 
Fleming, S.K., Blasey, C., Schatzberg, A.F. (2004). Neuropsychological Correlates of 
Psychotic Features in Major Depressive Disorders: a Review and Meta-Analysis. 
Journal of Psychiatric Research, Vol. 38 (2004), pp. 27-35, ISSN 0022-3956. 
Frangos, E., Athanassenas, G., Tsitourides, P., Psilolignos, P. & Katsanou, N. (1983). 
Psychotic Depressive Disorder: A Separate Entity? Journal of Affective Disorders, 
Vol.5, No.3, (August 1983), pp. 259-265, ISSN 0165-0327 
Gatti, F., Bellini, L., Gasperini, M., Perez, J.P., Zanardi, R. & Smeraldi, E. (1996). Fluvozamine 
Alone in the Treatment of Delusional Depression. American Journal of Psychiatry, 
Vol.153, No.3, (March 1996), pp. 414-416, ISSN 0002-953X 
www.intechopen.com
 
Mental Illnesses – Understanding, Prediction and Control 
 
256 
Glassman, A.H. & Roose, S.P. (1981). Delusional Depression: A Distinct Clinical Entity? 
Archives of General Psychiatry, Vol.38, No.4, (April 1981), pp. 424-427, ISSN 0003-
990X 
Gomez, R.G., Fleming, S.H., Keller, J., Flores, B., Kenna, H., DeBattista, C., Solvason, B., 
Schatzberg, A.F. (2006). The Neuropsychological Profile of Psychotic Major 
Depression and Its Relation to Cortisol. Biological Psychiatry, Vol. 60, No. 5 
(February 2006), pp. 472-8, ISSN 0006-3223. 
Guadiano, B.A. & Herbert, J.D. (2006). Acute Treatment of Inpatients with Psychotic 
Symptoms Using Acceptance and Commitment Therapy: Pilot Results. Behaviour 
Research and Therapy, Vol.44, No.3, (March 2006), pp. 415-437, ISSN 0005-7967 
Hamilton, M. (1960). A Rating Scale for Depression. Journal of Neurology, Neurosurgery, & 
Psychiatry, Vol.23, No.1, (February 1960), pp. 56-62, ISSN 00223050 
Hill, S.K., Keshavan, M.S., Thase, M.E., et al (2004). Neuropsychological Dysfunction in 
Antipsychotic-Naïve First-Episode Unipolar Psychotic Depression. American Journal 
of Psychiatry, Vol. 161 (2004), pp. 996-1003, ISSN 0002-953X. 
Hillert, A., Maier, W., Wetzel, H. & Benkert, O. (1992). Risperidone in the Treatment of 
Disorders with a Combined Psychotic and Depressive Syndrome – A Functional 
Approach. Pharmacopsychiatry, Vol.25, No.5, (September 1992), pp. 213-217, ISSN 
0176-3679 
Johnson, J., Horwath, E., Weissman, M.M. (1991). The Validity of Major Depression with 
Psychotic Features Based on a Community Sample. Arch Gen Psychiatry, Vol. 48 
(1991), pp. 1075-1081, ISSN 0003-990X. 
Kaiya, H. & Takeda, N. (1990). Sulpiride in the Treatment of Delusional Depression. Journal 
of Clinical Psychopharmacology, Vol.10, No.2, (April 1990), pp. 147, ISSN 0271-0749 
Keller, J., Gomez, R., Kenna, H., Poesner, J., DeBattista, C., Flores, B., Schatzberg, A. (2006). 
Detecting Psychotic Major Depression Using Psychiatric Rating Scales. Journal of 
Psychiatric Research, Vol. 40, Issue 1 (February 2006), pp. 22-29, ISSN 0022-3956. 
Kunugi, H., Ida, I., Owashi, T., Kimura, M., Inoue, Y., Nakagawa, S., Yabana, T., Urushibara, 
T., Kanai, R., Aihara, M., Yuuki, N., Otsubo, T., Oshima, A., Kudo, K., Inoue, T., 
Kitaichi, Y., Shirakawa, O., Isogawa, K., Nagayama, H., Kamijima, K., Nanko, S., 
Kanba, S., Higuchi, T., Mikuni, M (2006). Assessment of the Dexamethasone/CRH 
Test as a State-Dependent Marker for Hypothalamic-Pituitary-Adrenal (HPA) Axis 
Abnormalities in Major Depressive Episode: A Multicenter Study. 
Neuropsychopharmacology, Vol. 31 (2006), pp. 212-220, ISSN 0893-133X. 
Lane, H.Y. & Chang, W.H. (1998). Risperidone Monotherapy for Psychotic Depression 
Unresponsive to Other Treatments. Journal of Clinical Psychiatry, Vol.59, No.11, 
(November 1998), pp. 624, ISSN 0160-6689 
Langlais P.J., Rothschild A.J., Schatzberg A.F., Cole J.O., Bird E.D. (1984). Dexamethasone 
Elevates Dopamine in Human Plasma and Rat Brain. Psychopharmacol Bull., Vol. 20, 
No. 3 (Summer 1984), pp. 365-70, ISSN 0048-5764. 
Maj, M., Pirozzi, R., Magliano, L., Fiorillo, A. & Bartoli, L. (2007). Phenomenology and 
Prognostic Significance of Delusions in Major Depressive Disorder: A 10-Year 
Prospective Follow-Up Study. Journal of Clinical Psychiatry, Vol.68, No.9, 
(September 2007), pp. 1411-1417, ISSN 0160-6689 
Matthews, J.D., Bottonari, K.A., Polania, L.M., Mischoulon, D., Dording, C.M., Irving, R., 
Fava, M. (2002). An Open Study of Olanzapine and Fluoxetine for Psychotic Major 
www.intechopen.com
 
An Update on Psychotic Depression 
 
257 
Depressive Disorder: Interim Analyses. Journal of Clinical Psychiatry, Vol. 63, No. 12 
(December 2002), pp. 1164-70, ISSN 0160-6689. 
Matthews, J.D., Siefert, C., Dording, C., Denninger, J.W., Park, L., van Nieuwenhuizen, A.O., 
Sklarsky, K., Hilliker, S., Homberger, C., Rooney, K., Fava, M. (2009). An Open 
Study of Aripiprazole and Escitalopram for Psychotic Major Depressive Disorder. 
Journal of Clinical Psychopharmacology, Vol. 29, No. 1 (February 2009), pp. 73-6, ISSN 
0271-0749. 
Matthews, J.D. (2010). Improvements in Cognitive Functioning During Inpatient 
Hospitalization for Unipolar and Bipolar Depression with and Without Psychotic 
Features. Poster Presentation, American Psychiatric Association Annual Meeting, 
New Orleans, LA, 2010. 
Matthews, J.D. (2001). Psychotic Major Depression: Prescribing Practices – 304 Clinicians 
Surveyed. Unpublished Data (2001). 
Meyers, B.S., Flint, A.J., Rothschild, A.J., Mulsant, B.H., Whyte, E.M., Peasley-Miklus, C., 
Papademetriou, E., Leon, A.C. & Heo, M. (2009). A Double-Blind Randomized 
Controlled Trial of Olanzapine Plus Sertraline versus Olanzapine Plus Placebo for 
Psychotic Depression. Archives of General Psychiatry, Vol.66, No.8, (August 2009), 
pp. 838-847, ISSN 0003-990X 
Muller-Siecheneder, F., Muller, M.J., Hillert, A., Szegedi, A., Wetzel, H. & Benkert, O. (1998). 
Risperidone versus Haloperidol and Amitriptyline in the Treatment of Patients 
with a Combined Psychotic and Depressive Syndrome. Journal of Clinical 
Psychopharmacology, Vol.18, No.2, (April 1998), pp. 111-120, ISSN 0271-0749 
Mulsant, B.H., Hasket, R.F., Prudic, J., Thase, M.E., Malone, K.M., Mann, J.J., Pettinatie, H.M. 
& Sackeim, H.A. (1997). Low Use of Neuroleptic Drugs in the Treatment of 
Psychotic Major Depression. American Journal of Psychiatry, Vol.154, No.4. (April 
1997), pp. 559-561, ISSN 0002-953X 
Nelson, J.C. & Davis, J.M. (1997). DST Studies in Psychotic Depression: A Meta-Analysis. 
American Journal of Psychiatry, Vol.154, No.11, (November 1997), pp. 1497-1503, 
ISSN 0002-953X 
Ohayon, M.M. & Schatzberg, A.F. (2002). Prevalence of Depressive Episodes with Psychotic 
Features in the General Population. American Journal of Psychiatry, Vol.159, No.11, 
(November 2002), pp.1855-1861, ISSN 0002-953X 
Pariante, C.M. & Miller, A.H. (2001). Glucocorticoid Receptors in Major Depression: 
Relevance to Pathophysiology and Treatment. Biological Psychiatry, Vol.49, No.5, 
(March 2001), pp. 391-404, ISSN 0006-3223 
Petrides, G., Fink, M., Husain, M.M., Knapp, R.G., Rush, A.J., Mueller, M., Rummans, T.A., 
O’Connor, K.M., Rasmussen, K.G., Berstein, H.J., Biggs, M., Bailine, S.H. & Keller, 
C.H. (2001). ECT Remission Rates in Psychotic versus Nonpsychotic Depressed 
patients: A Report from CORE. Journal of ECT, Vol.4, No.4, (December 2001), pp. 
244-253, ISSN 1095-0680 
Ranyan, R. & Meltzer, H.Y. (1996). Acute and Long-Term Effectiveness of Clozapine in 
Treatment-Resistant Psychotic Depression. Biological Psychiatry, Vol.40, No.4, 
(August 1996), pp. 253-258, ISSN 0006-3223 
Reddy, P.L., Khanna, S., Subhash, M.N., Channabasavanna, S.M., Sridhara Rama Rao, B.S 
(1992). CSF Amine Metabolites in Depression. Biological Psychiatry, Vol. 31, (1992), 
pp. 112-118, ISSN 0006-3223. 
www.intechopen.com
 
Mental Illnesses – Understanding, Prediction and Control 
 
258 
Robinson, D.G., Spiker, D.G. (1985). Delusional Depression: A One Year Follow-Up. Journal 
of Affective Disorders, Vol. 9 (1985), pp. 79-83, ISSN 0165-0327. 
Rothschild, A., Langlais, P., Schatzberg, A., Walsh, F., Cole, J., Bird, E. (1984). 
Dexamethasone Increases Plasma Free Dopamine in Man. Journal of Psychiatric 
Research, Vol. 18, No. 3 (1984), pp. 217-223, ISSN 0022-3956. 
Rothschild, A.J., Bates, K.S., Boehringer, K.L. & Syed, A. (1999). Olanzapine Response in 
Psychotic Depression. Journal of Clinical Psychiatry, Vol.60, No.2, (February 1999), 
pp. 116-118, ISSN 0160-6689 
Rothschild, A.J. & Phillips, K.A. (1999). Selective Serotonin Reuptake Inhibitors and 
Delusional Depression. American Journal of Psychiatry, Vol.156, No.6, (June 1999), 
pp. 977-978, ISSN 0002-953X 
Rothschild, A.J. & Duval, S.E. (2003). How Long Should Patients with Psychotic Depression 
Stay on the Antipsychotic Medication? Journal of Clinical Psychiatry, Vol.64, No.4, 
(April 2003), pp. 390-396, ISSN 0160-6689 
Rothschild, A.J., Schatzberg, A.F., Langlais, P.J., Lerbinger, J.E., Miller, M.M., Cole, J.O 
(1987). Psychotic and Nonpsychotic Depressions: I. Comparison of Plasma 
Catecholamines and Cortisol Measures. Psychiatry Res, Vol. 20, No. 2, (Feb 1987), 
pp. 143-53, ISSN 0165-1781. 
Rothschild, A.J., Schatzberg, A.F., Rosenbaum, A.H., et al (1982). The Dexamethasone 
Suppression Test as a Discriminator Among Subtypes of Psychotic Patients. British 
Journal of Psychiatry, Vol. 141 (1982), pp. 471-474, ISSN 0007-1250. 
Rothschild, A.J., Williamson, D.J., Tohen, M.F., Schatzberg, A., Andersen, S.W., Van 
Campen, L.E., Sanger, T.M. & Tollefson, G.D. (2004). A Double-Blind, Randomized 
Study of Olanzapine and Olanzapine/Fluoxetine Combination for Major 
Depression with Psychotic Features. Journal of Clinical Psychopharmacology, Vol.24, 
No.4, (August 2004), pp. 365-373, ISSN 0271-0749 
Rothschild, A.J., Winer, J., Flint, A.J., Mulsant, B.H., Whyte, E.M., Heo, M., Fratoni, S., 
Gabriele, M., Kasapinovic, S. & Meyers, B.S. (2008). Missed Diagnosis of Psychotic 
Depression at 4 Academic Medical Centers. Journal of Clinical Psychiatry, Vol.69, 
No.8, (August 2008), pp. 1293-1296, ISSN 0160-6689 
Rothschild, AJ (2009). Clinical Manual for Diagnosis and Treatment of Psychotic Depression, 
American Psychiatric Association ISBN 978-1-58562-292-4, Washington, DC. 
Rush, A.J., Beck, A.T., Kovacs, M., Hollon, S. (1977). Comparative Efficacy of Cognitive 
Therapy and Pharmacotherapy in the Treatment of Depressed Outpatients. 
Cognitive Therapy Research, Vol. 1 (1997), pp. 17-37, ISSN 0147-5916. 
Schatzberg, A. & Rothschild, A.J. (1992). Psychotic (Delusional) Major Depression: Should it 
be Included as a Distinct Syndrome in DSM-IV? American Journal of Psychiatry, 
Vol.149, No.6, (June 1992), pp. 733-745, ISSN 0002-953X 
Schatzberg, A.F., Rothschild, A.J., Langlais, P.J., et al (1985). A Corticosteroid/Dopamine 
Hypothesis for Psychotic Depression and Related States. Journal Psychiatric 
Research, Vol. 19 (1985), pp. 57-64, ISSN 0022-3956. 
Schatzberg, A.F., Rothschild, A.J., Stahl, J.B., Bond, T.C., Rosenbaum, A.H., Lofgen, S.B., 
MacLaughlin, R.A., Sullivan, M.A., Cole, J.O. (1983). The Dexamethasone 
Suppression Test: Identification of Subtypes of Depression. American Journal of 
Psychiatry, Vol. 140, No. 1 (January 1983), pp. 88-91. 
www.intechopen.com
 
An Update on Psychotic Depression 
 
259 
Sher, L., Mann, J.J., Traskman-Bendz, L., Winchel, R., Huang, Y., Fertuck, E., Stanley, B. 
Lower Cerebrospinal Fluid Homovanillic Acid Levels in Depressed Suicide 
Attempters. Journal of Affective Disorders, Vol. 90, Iss. 1 (January 2006), pp. 83-89, 
ISSN 0165-0327. 
Simpson, G.M., Sheshai, A., Rady, A., Kingsbury, S.J. & Fayek, M. (2003). Sertraline as 
Monotherapy in the Treatment of Psychotic and Nonpsychotic Depression. Journal 
of Clinical Psychiatry, Vol.64, No.8, (August 2003), pp. 959-965, ISSN 0160-6689 
Solan, W.J., Khan, A., Avery, D.H. & Cohen, S. (1988). Psychotic and Nonpsychotic 
Depression: Comparison of Response to ECT. Journal of Clinical Psychiatry, Vol.49, 
No.3, (March 1988), pp. 97-99, ISSN 0160-6689 
Spiker, D.G., Cofsky, W.J., Dealy, R.S., Griffin, S.J., Hanin, I., Neil, J.F., Perel, J.M., Rossi, A.J. 
& Soloff, P.H. (1985). The Pharmacological Treatment of Delusional Depression. 
American Journal of Psychiatry, Vol.142, No.4, (April 1985), pp. 430-436, ISSN 0002-
953X 
Strober, M., Carlson, G. (1982). Bipolar Illness in Adolescents with Major Depression: 
Clinical, Genetic, and Psychopharmacologic Predictors in a Three to Four Year 
Prospective Follow-Up Investigation. Arch Gen Psychiatry, Vol. 39 (1982), pp. 549-
555, ISSN  0003-990X. 
Sullivan, P., Kendler, K. (2001). Genetic Case-control Studies in Neuropsychiatry. Arch Gen 
Psychiatry, Vol. 58 (2001), pp. 1015-1024, ISSN 0003-990X. 
Thakore, J.H. & Dinan, T.G. (1995). Cortisol Synthesis Inhibition: A New Treatment Strategy 
for the Clinical and Endocrine Manifestations of Depression. Biological Psychiatry, 
Vol.37, No.6, (March 1995), pp. 364-368, ISSN 0006-3223 
Tsuang, D. & Coryell, W. (1993). An 8-Year Follow-Up of Patients with DSM-III-R Psychotic 
Depression, Schizoaffective Disorder, and Schizophrenia. American Journal of 
Psychiatry, Vol.150, No.8, (August 1993), pp. 1182-1188, ISSN 0002-953X 
Vythilingam, M., Chen, J., Bremner, J.D., Mazure, C.M., Maciejewski, P., Nelson, J.C. (2003). 
Psychotic Depression and Mortality. American Journal of Psychiatry, Vol. 160, No. 3 
(March 2003), pp. 574-576, ISSN 0002-953X. 
Weissman, M.M., Prusoff, B.A., Merikangas, K.R. (1984). Is Delusional Depression Related to 
Bipolar Disorder? American Journal of Psychiatry, Vol. 141 (1984), pp. 892-893, 
ISSN 0002-953X. 
Weissman, M.M., Warner, V., Prusoff, J.K., et al (1988). Delusional Depression and Bipolar 
Sepctrum: Evidence for a Possible Association From a Family Study of Children. 
Neuropsychopharmacology, Vol. 1 (1988), pp. 257-264. 
Wijkstra, J., Burger, H., van den Broek, W.W., Birkenhager, T.K., Janzing, J.G.E., Boks, 
M.P.M., Bruijn, J.A., van der Loos M.L.M., Breteler, L.M.T., Ramaekers, G.M.G.I., 
Verkes, R.J. & Nolen, W.A. (2010a). Treatment of Unipolar Psychotic Depression: A 
Randomized, Double-Blind Study Comparing Imipramine, Venlafaxine, and 
Venlafaxine Plus Quetiapine. Acta Psychiatrica Scandinavica, Vol.121, No.3, (March 
2010), pp. 190-200, ISSN 0001-690X 
Wijkstra, J., Burger, H., van den Broek, W.W., Birkenhager, T.K., Janzing, J.G.E., Boks, 
M.P.M., Bruijn, J.A., van der Loos M.L.M., Breteler, L.M.T., Verkes, R.J. & Nolen, 
W.A. (2010b). Long-Term Response to Successful Actue Pharmacological Treatment 
of Psychotic Depression. Journal of Affective Disorders, Vol.123, No.1-3, (June 2010), 
pp. 238-242, ISSN 0165-0327 
www.intechopen.com
 
Mental Illnesses – Understanding, Prediction and Control 
 
260 
Wolkowitz, O.M., Doran, A.R., Breier, A., Roy, A., Jimerson, D., Sutton, M., Golden, R., Paul, 
S., Pickar, D (1987). The Effects of Dexamethasone on Plasma Homovanillic Acid 
and 3-Methoxy-4-hydroxyphenylglycol. Arch Gen Psychiatry, Vol. 44 (Sept 1987), 
pp. 782-1017, ISSN 0003-990X. 
Wolkowitz, O.M., Reus, V.I., Chan, T., Manfredi, F., Raum, W., Johnson, R. & Canick, J. 
(1999). Antiglucocorticoid Treatment of Depression: Double-Blind Ketoconazole. 
Biological Psychiatry, Vol.45, No.8, (April 1999), pp. 1070-1074, ISSN 0006-3223 
Wood, J.G., Joyce, P.R., Miller, A.L., et al (2002). A Polymorphism in the Dopamine Beta-
Hydroxyglase Gene is Associated with “Paranoid Ideation” in Patients with Major 
Depression. Biological Psychiatry, Vol. 51 (2002), pp. 365-376, ISSN 0002-3223. 
Young, E.A., Haskett, R.F., Murphy-Weinberg, V., Watson, S.J. & Akil, H. (1991). Loss of 
Glucocorticoid Fast Feedback in Depression. Archives of General Psychiatry, Vol.48, 
No.8, (August 1991), pp. 693-699, ISSN 0003-990X 
Zanardi, R., Franchini, L., Gasperini, M., Perez, J. & Smeraldi, E. (1996). Double-Blind 
Controlled Trial of Sertraline versus Paroxetine in the Treatment of Delusional 
Depression. American Journal of Psychiatry, Vol.153, No.12, (December 1996), pp. 
1631-1633, ISSN 0002-953X 
Zanardi, R., Franchini, L., Gasperini, M., Smeraldi, E. & Perez, J. (1997). Long-Term 
Treatment of Psychotic (Delusional) Depression with Fluvoxamine: And Open Pilot 
Study. International Clinical Psychopharmacology, Vol.12, No.4, (July 1997), pp. 195-
197, ISSN 0268-1315 
Zanardi, R., Franchini, L., Serretti, A., Perez, J. & Smeraldi, E. (2000). Venlafaxine versus 
Fluvoxamine in the Treatment of Delusional Depression: A Pilot Double-Blind 
Controlled Study. Journal of Clinical Psychiatry, Vol.61, No.1, (January 2000), pp. 26-
29, ISSN 0160-6689 
www.intechopen.com
Mental Illnesses - Understanding, Prediction and Control
Edited by Prof. Luciano LAbate
ISBN 978-953-307-662-1
Hard cover, 458 pages
Publisher InTech
Published online 05, January, 2012
Published in print edition January, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
In the book "Mental Illnesses - Understanding, Prediction and Control" attention is devoted to the many
background factors that are present in understanding public attitudes, immigration, stigma, and competencies
surrounding mental illness. Various etiological and pathogenic factors, starting with adhesion molecules at one
level and ending with abuse and maltreatment in childhood and youth at another level that are related to
mental illness, include personality disorders that sit between mental health and illness. If we really understand
the nature of mental illness then we should be able to not only predict but perhaps even to control it
irrespective of the type of mental illness in question but also the degree of severity of the illness in order to
allow us to predict their long-term outcome and begin to reduce its influence and costs to society. How can we
integrate theory, research evidence, and specific ways to deal with mental illness? An attempt will be made in
the last conclusive chapter of this volume.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
John Matthews (2012). An Update on Psychotic Depression, Mental Illnesses - Understanding, Prediction and
Control, Prof. Luciano LAbate (Ed.), ISBN: 978-953-307-662-1, InTech, Available from:
http://www.intechopen.com/books/mental-illnesses-understanding-prediction-and-control/an-update-on-
psychotic-depression
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
